Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as SPY002
SPY002-091 · 1 trial · 1 indication
Incidence, severity, and causal relationship of TEAEs
| Arm | Type | Description |
|---|---|---|
| SAD Cohorts 1-5, Experimental Arm | EXPERIMENTAL | Participants will receive a single dose of SPY002-091 in a dose escalation format |
| SAD Cohorts 1-5, Placebo Arm | PLACEBO_COMPARATOR | Participants will receive a single dose of placebo |
| SAD Cohort 6 Experimental Arm | EXPERIMENTAL | Participants of Chinese descent will receive a single dose of SPY002-091 |
| SAD Cohorts 6 Placebo Arm | PLACEBO_COMPARATOR | Participants of Chinese descent will receive a single dose of placebo |
| Name | Type | Description |
|---|---|---|
| SPY002-091 | DRUG | Experimental |
| Placebo | OTHER | Placebo |
Inclusion Criteria: * Healthy men and women * Willing and able to attend the necessary visits to the CRU, comply with all testing requirements, remain at the study site unit for the duration of the confinement period and return for the outpatient visits Exclusion Criteria: * Participation in more...
SPY002-091 is an investigational small molecule developed by Spyre Therapeutics, Inc. (ticker SYRE). It has been studied in a Phase 1 clinical trial in healthy adult volunteers in the United States. The specific disease indications being pursued for SPY002-091 have not been publicly disclosed.
SPY002-091 is being developed by Spyre Therapeutics, Inc., which trades on the Nasdaq under the ticker SYRE. Spyre is the sponsor of the clinical program evaluating this small molecule asset.
SPY002-091 is in Phase 1 clinical development. Its single reported trial, NCT06672718, was a Phase 1 study in healthy volunteers that has been completed. The drug remains investigational and is not approved by the FDA.
SPY002-091 has been evaluated in one clinical trial, NCT06672718, titled A Study of SPY002-091 in Healthy Volunteers. The Phase 1 trial enrolled 50 participants in the United States, was randomized, double-blind, and placebo-controlled, and has been completed.
The Phase 1 trial NCT06672718 studied SPY002-091 in 50 healthy adult volunteers aged 18 years and older in the United States. It was a randomized, double-blind, placebo-controlled study, and it has been completed.